

**Date: January 17, 2026**

<b>BSE Limited</b> 14 <sup>th</sup> Floor, P. J. Towers, Dalal Street, Fort, Mumbai - 400001.	<b>Stock ID: TLL</b> <b>Scrip Code: 543616</b>
--	---

**Sub: Outcome of Board Meeting held on 17.01.2026**

We wish to inform you that the Board of Directors, at their meeting held today- Saturday, January 17, 2026, has transacted, approved, and taken on record the following items of Business;

**1. Approval of Un-Audited Standalone and Consolidated Financial Results:**

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2025. (The copy of Un-Audited Standalone & Consolidated Financial results along with Limited Review Report of Auditors thereon is attached herewith as **(Annexure-A)**).

Further, pursuant to the provisions of Regulation 47 of the SEBI Listing Regulations, an extract of the aforementioned Financial Results would be published in the newspapers in accordance with the SEBI Listing Regulations, and the same will be made available on the Company's website at <http://www.tridentlifeline.com/>.

The Board Meeting commenced at 06:00 p.m. and concluded at 07:05 p.m.

You are requested to kindly take the note of above on records.

Thanking You,

Yours Faithfully  
For **Trident Lifeline Limited**

**Nikita Sharma**  
**Company Secretary and Compliance Officer**  
**M. No.: A60595**

**Encl: As Above**

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT**

**Limited Review Report on unaudited standalone financial results of Trident Lifeline Limited for the quarter ended 31<sup>st</sup> December, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**


**To Board of Directors**

**TRIDENT LIFELINE LIMITED**

2nd Floor, Shop-2004,  
North Extension, Falsawadi,  
Begumpura, Sahara Darwaja,  
Surat, Gujarat - 395003

1. We have reviewed the accompanying statement of Unaudited Standalone Financial result of **TRIDENT LIFELINE LIMITED** for the quarter ended on 31<sup>st</sup> December, 2025. This Statement is responsibility of the Company's Management and has been approved by its Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the statement in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Bafna & Associates  
Chartered Accountants  
(Firm Reg. No:- 121901W)



CA Meet Prakashkumar Jain  
Partner  
M. NO. 195377



ICAI UDIN NO.: 26195377KPJWVW7823  
Place : Surat  
Date : 17<sup>th</sup> January, 2026


Standalone Profit And Loss Statement of Unaudited Financial Results for the Quarter & Nine Months ended 31st December, 2025						
(Amount In Lacs)						
Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025 Unaudited (CY Q3)	30.09.2025 Unaudited (CY Q2)	31.12.2024 Unaudited (PY Q3)	31.12.2025 Unaudited (CY 9M)	31.12.2024 Unaudited (PY 9M)	31.03.2025 Audited FY 2024-25
<b>I. Revenue From Operations</b>						
Net Sales/Income From Operations (Net of Taxes)	2,367.09	2,744.03	1,650.88	6,992.94	4,690.69	6,779.91
Other Income	89.21	110.67	53.89	253.53	152.90	314.08
<b>TOTAL INCOME</b>	<b>2,456.30</b>	<b>2,854.70</b>	<b>1,704.76</b>	<b>7,246.47</b>	<b>4,843.59</b>	<b>7,094.00</b>
<b>II. EXPENSES</b>						
Cost of Materials Consumed	1,552.03	1,615.90	867.75	4,312.30	2,472.07	3,285.59
Purchase of Stock-in-Trade	52.54	48.16	24.45	166.79	150.51	187.96
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(193.39)	(59.93)	(28.30)	(402.91)	(139.72)	147.06
Employment Benefit Expenses	78.98	93.40	84.55	259.37	207.73	306.95
Financial Costs	53.70	41.78	35.06	128.06	77.12	122.83
Depreciation and Amortization Expenses	71.23	59.36	37.87	181.78	113.19	152.87
Other Expenses	248.82	408.14	288.63	933.48	744.54	1,100.16
<b>TOTAL EXPENSES</b>	<b>1,863.90</b>	<b>2,206.82</b>	<b>1,310.01</b>	<b>5,578.87</b>	<b>3,625.45</b>	<b>5,303.42</b>
<b>III. Profit Before Exceptional and Extraordinary Items and Tax</b>	<b>592.39</b>	<b>647.87</b>	<b>394.76</b>	<b>1,667.60</b>	<b>1,218.14</b>	<b>1,790.58</b>
<b>IV. Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>V. Profit Before Extraordinary Items and Tax</b>	<b>592.39</b>	<b>647.87</b>	<b>394.76</b>	<b>1,667.60</b>	<b>1,218.14</b>	<b>1,790.58</b>
<b>VI. Extraordinary Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>VII. Profit Before Tax</b>	<b>592.39</b>	<b>647.87</b>	<b>394.76</b>	<b>1,667.60</b>	<b>1,218.14</b>	<b>1,790.58</b>
<b>VIII. Tax Expense :</b>						
(1) Current Tax	(183.92)	(153.75)	(92.00)	(452.67)	(302.00)	(425.00)
(2) MAT Credit	-	-	-	-	-	-
(3) Excess Tax Provision of Earlier Year	-	-	-	-	-	-
(4) Deferred Tax	(7.01)	-	-	(7.01)	-	(60.44)
<b>IX. Net Profit/(Loss) for the Period</b>	<b>401.46</b>	<b>494.12</b>	<b>302.76</b>	<b>1,207.93</b>	<b>916.14</b>	<b>1,305.14</b>
<b>X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)</b>	<b>1,193.30</b>	<b>1,159.22</b>	<b>1,149.92</b>	<b>1,193.30</b>	<b>1,149.92</b>	<b>1,149.92</b>
<b>XI. Earning Per Equity Share:</b>						
(1) Basic- Not Annualized	3.47	4.26	2.63	10.43	7.97	11.35
(2) Diluted- Not Annualized	3.47	4.26	2.63	10.43	7.97	11.35

For And On Behalf Of The Board

TRIDENT LIFELINE LIMITED



Chairman &  
Executive Director  
Hardik Desai  
(DIN No: 01358227)



CFO &  
Executive Director  
Ashish Bafna  
(DIN No: 01796556)



Managing  
Director  
Shravan H. Patel  
(DIN No: 08629141)

## **Notes to Financial Results**

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the period ended as on 31st December, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 17<sup>th</sup>, 2026.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
4. As per management's current assessment, no significant impact on carrying amounts of inventories, trade receivables, investments and other financial assets is expected, and management will continue to monitor changes in future economic conditions. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these Standalone Financial statements.
5. As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to the rule 4 of Companies (Indian Accounting Standards), 2015
6. The status of Investor's Complaints during the year ended on 31st December, 2025 is as under:


Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed of and resolved during the period	Nil
Complaints pending at the end of the period	Nil

For Trident Lifeline Limited



Chairman &  
Executive Director  
Hardik Desai  
(DIN:- 01358227)

For Trident Lifeline Limited



CFO &  
Executive Director  
Ashish Bafna  
(DIN No: 01796556)

For Trident Lifeline Limited



Managing  
Director  
Shravan H. Patel  
(DIN:- 08629141)

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT**

**Independent Auditor's Review Report on unaudited consolidated financial results of Trident Lifeline Limited for the quarter & nine months ended on 31<sup>st</sup> December, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To Board of Directors of**

**TRIDENT LIFELINE LIMITED**

2nd Floor, Shop-2004,  
North Extension, Falsawadi,  
Begumpura, Sahara Darwaja,  
Surat, Gujarat - 395003

1. We have reviewed the accompanying statement of unaudited consolidated financial result of **TRIDENT LIFELINE LIMITED** and its subsidiaries **TNS PHARMA PRIVATE LIMITED, TLL HERBAL LIMITED, TLL PARENTERALS LIMITED, TRIDENT MEDQUIP LIMITED & TLL ELEMENTS PRIVATE LIMITED** (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended on 31<sup>st</sup> December, 2025 and for the period from 01<sup>st</sup> April, 2025 to 31<sup>st</sup> December, 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended on 31<sup>st</sup> December, 2025 and the corresponding period from 01<sup>st</sup> April, 2025 to 31<sup>st</sup> December, 2025, as reported in these financial results have been approved by the Parent's Board of Directors.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

- a) M/s. Trident Lifeline Limited (The parent company)
- b) M/s. TNS Pharma Private Limited (The subsidiary company)
- c) M/s. TLL Parenterals Limited (The subsidiary company)
- d) M/s. Trident Mediquip Limited (The subsidiary company)
- e) M/s. TLL Elements Private Limited (The subsidiary company)
- f) M/s. TLL Herbal Limited (The subsidiary company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Bafna & Associates  
Chartered Accountants  
(Firm Reg. No.- 121901W)



CA Meet Prakashkumar Jain

Partner

M. NO. 195377

UDIN NO.: 26195377COPDJF8104

Place : Surat

Date : 17<sup>th</sup> January, 2026




Statement of Unaudited Consolidated Financial Results for the Quarter & Nine Months ended 31st December, 2025						
Particulars	(Amount in Lacs)					
	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2025 Unaudited (CY Q3)	30.09.2025 Unaudited (CY Q2)	31.12.2024 Unaudited (PY Q3)	31.12.2025 Unaudited (CY 9M)	31.12.2024 Unaudited (PY 9M)	31.03.2025 Audited FY 2024-25
<b>I. Revenue From Operations</b>						
Net Sales/Income From Operations (Net of Taxes)	2,571.11	3,133.70	1,182.66	8,061.05	4,091.91	8,696.47
Other Income	462.58	166.91	55.91	741.95	159.58	823.11
<b>TOTAL INCOME</b>	<b>3,033.69</b>	<b>3,300.61</b>	<b>1,238.57</b>	<b>8,803.01</b>	<b>4,251.49</b>	<b>9,519.58</b>
<b>II. EXPENSES</b>						
Cost of Materials Consumed	1,747.05	1,830.39	417.62	4,829.29	2,017.73	4,304.63
Purchase of Stock-in-Trade	52.42	116.96	24.45	197.30	126.91	179.59
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(294.25)	(133.35)	(69.71)	(668.76)	(219.55)	71.00
Employment Benefit Expenses	253.21	338.07	133.65	859.71	323.90	1,208.84
Financial Costs	123.69	98.72	55.17	312.14	149.54	398.52
Depreciation and Amortization Expenses	246.23	91.14	60.87	483.41	181.95	549.25
Other Expenses	303.14	295.82	268.90	1,138.60	695.14	1,446.27
<b>TOTAL EXPENSES</b>	<b>2,431.49</b>	<b>2,637.75</b>	<b>890.95</b>	<b>7,151.70</b>	<b>3,275.62</b>	<b>8,158.10</b>
<b>III. Profit Before Exceptional and Extraordinary Items and Tax</b>	<b>602.20</b>	<b>662.86</b>	<b>347.62</b>	<b>1,651.30</b>	<b>975.87</b>	<b>1,361.49</b>
<b>IV. Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>V. Profit Before Extraordinary Items and Tax</b>	<b>602.20</b>	<b>662.86</b>	<b>347.62</b>	<b>1,651.30</b>	<b>975.87</b>	<b>1,361.49</b>
<b>VI. Extraordinary Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>VII. Profit Before Tax</b>	<b>602.20</b>	<b>662.86</b>	<b>347.62</b>	<b>1,651.30</b>	<b>975.87</b>	<b>1,361.49</b>
<b>VIII. Tax Expense :</b>						
(1) Current Tax	(184.07)	(153.75)	(92.00)	(452.82)	(302.00)	(453.80)
(2) MAT Credit	-	-	-	-	-	-
(3) Excess Tax Provision of Earlier Year	(2.39)	-	-	(2.39)	-	(0.38)
(4) Deferred Tax	49.04	-	-	49.04	-	142.18
<b>IX. Net Profit/(Loss) for the Period</b>	<b>464.78</b>	<b>509.11</b>	<b>255.62</b>	<b>1,245.14</b>	<b>673.87</b>	<b>1,049.48</b>
Minority Interest	34.35	14.26	(23.10)	34.51	(118.72)	(125.31)
<b>Profit for the Year after Minority Interest</b>	<b>430.44</b>	<b>494.85</b>	<b>278.72</b>	<b>1,210.63</b>	<b>792.58</b>	<b>1,174.79</b>
Profit/(Loss) From Discontinuing Operations	-	-	-	-	-	-
Tax Expense of Discontinuing Operations	-	-	-	-	-	-
Profit/(Loss) From Discontinuing Operations	-	-	-	-	-	-
Balance Transferred to Pre-operative Expenses	-	-	-	-	-	-
<b>Profit/(Loss) For The Period</b>	<b>430.44</b>	<b>494.85</b>	<b>278.72</b>	<b>1,210.63</b>	<b>792.58</b>	<b>1,174.79</b>
<b>X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)</b>	<b>1,193.30</b>	<b>1,159.92</b>	<b>1,149.92</b>	<b>1,193.30</b>	<b>1,149.92</b>	<b>1,149.92</b>
<b>XI. Earning Per Equity Share:</b>						
(1) Basic- Not Annualized	3.72	4.27	2.42	10.45	6.89	10.22
(2) Diluted- Not Annualized	3.72	4.27	2.42	10.45	6.89	10.22

For And On Behalf Of The Board

TRIDENT LIFELINE LIMITED



Chairman &  
Executive Director  
Hardik Desai  
(DIN No: 01358227)



CFO &  
Executive Director  
Ashish Bafna  
(DIN No: 01796556)



Managing  
Director  
Shravan H. Patel  
(DIN No: 08629141)

## Notes to Financial Results

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the period ended on 31<sup>st</sup> December, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 17<sup>th</sup> January, 2026.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
4. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TNS Pharma Pvt. Ltd. and became holding company as on 21/12/2022. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 31/12/2025 (Quarter & 9 Months ended) by consolidating Assets and Liabilities of M/s. TNS Pharma Pvt. Ltd.
5. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TLL Herbal Ltd. and became holding company as on 10/08/2023. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 31/12/2025 (Quarter & 9 Months ended) by consolidating Assets and Liabilities of M/s. TLL Herbal Ltd.
6. M/s. Trident Lifeline Limited has acquired 100% shareholding of M/s. TLL Elements Pvt. Ltd. and became holding company as on 15/04/2024. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 31/12/2025 (Quarter & 9 Months ended) by consolidating Assets and Liabilities of M/s. TLL Elements Pvt. Ltd.
7. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TLL Parenterals Pvt. Ltd. and became holding company as on 02/12/2024. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 31/12/2025 (Quarter & 9 Months ended) by consolidating Assets and Liabilities of M/s. TLL Elements Pvt. Ltd.
8. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. Trident Mediquip Ltd. and became holding company as on 04/02/2025. Moreover, M/s. Trident Lifeline Limited acquired 9.04% shareholding of M/s Trident Mediquip Ltd on 31/12/2025. So the shareholding of M/s. Trident Lifeline Limited in M/s. Trident Mediquip Ltd has changed to 60.04% w.e.f. 31/12/2025. Hence, we have prepared Consolidated Financial Statements of M/s. Trident Lifeline Limited as on 31/12/2025 (Quarter & 9 Months ended) by consolidating Assets and Liabilities of M/s. Trident Mediquip Ltd.
9. As per management's current assessment, no significant impact on carrying amounts of inventories, trade receivables, investments and other financial assets is expected, and management will continue to monitor changes in future economic conditions. The eventual outcome of the impact of the global health pandemic may be different from those estimated as on the date of approval of these Consolidated Financial statements.
10. As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to the rule 4 of Companies (Indian Accounting Standards), 2015

**11. The status of Investor's Complaints during the year ended on 31<sup>st</sup> December, 2025 is as under:**

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed of and resolved during the period	Nil
Complaints pending at the end of the period	Nil


**For Trident Lifeline Limited**

**For Trident Lifeline Limited**

**For Trident Lifeline Limited**



Chairman &  
Executive Director  
Hardik Desai  
(DIN:- 01358227)



CFO &  
Executive Director  
Ashish Bafna  
(DIN No: 01796556)



Managing  
Director  
Shravan H. Patel  
(DIN:- 08629141)

**Date:- 17<sup>th</sup> January, 2026**

**Place:- Surat**